Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 261 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 EMA Recommends Extension of Indications for Olaparib September 24, 2020 Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Load more HOT NEWS What to Know About Navigating Your Cancer Care During An Extreme... EMA Recommends Granting a Marketing Authorisation for Capivasertib “Oncometabolite” Neutralizes Immune Cells Near Tumors Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention...
